Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
0.5601
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
These stocks that are showing activity before the opening bell on Friday.
↗
April 25, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
Dow Falls 200 Points; Alphabet Posts Upbeat Q1 Results
↗
April 25, 2025
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
April 25, 2025
Via
Benzinga
Lexaria Announces $2 Million Registered Direct Offering of Common Stock
April 25, 2025
Via
ACCESS Newswire
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
February 27, 2025
Via
ACCESS Newswire
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
February 24, 2025
Via
ACCESS Newswire
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
April 23, 2025
Via
ACCESS Newswire
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
April 03, 2025
Via
ACCESS Newswire
Lexaria's Human GLP-1 Study #5 Begins Dosing
April 02, 2025
Via
ACCESS Newswire
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
March 18, 2025
Via
ACCESS Newswire
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
February 20, 2025
Via
ACCESS Newswire
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
February 11, 2025
Via
ACCESS Newswire
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
February 06, 2025
Via
ACCESS Newswire
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
February 05, 2025
Via
ACCESS Newswire
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
January 15, 2025
Via
ACCESSWIRE
Lexaria Releases Annual Letter from the CEO
January 30, 2025
Via
ACCESS Newswire
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
January 14, 2025
Via
ACCESSWIRE
Lexaria Bioscience Earnings Analysis: Q1 Recap
↗
January 10, 2025
Via
Benzinga
Lexaria's Registered GLP-1 Study #4 Begins Dosing
December 19, 2024
Via
ACCESSWIRE
Lexaria Forms New Scientific Advisory Board
December 18, 2024
Via
ACCESSWIRE
Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
December 17, 2024
Via
ACCESSWIRE
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
December 09, 2024
Via
ACCESSWIRE
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
November 26, 2024
Via
ACCESSWIRE
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
November 25, 2024
Via
ACCESSWIRE
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
November 14, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights Expanding Opportunities in GLP-1 Drug Market and Strategic Focus on DehydraTECH Integration
December 03, 2024
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights Expanding Opportunities in GLP-1 Drug Market and Strategic Focus on DehydraTECH Integration
December 03, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
November 20, 2024
Via
ACCESSWIRE
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
November 13, 2024
Via
ACCESSWIRE
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
November 07, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
